Pharmacotherapy of heart failure with preserved ejection fraction

Czech version

Authors: T. Andreasová; F. Málek
Authors‘ workplace: Kardiocentrum, Nemocnice Na Homolce, Praha
Published in: Kardiol Rev Int Med 2017, 19(2): 128-130

Overview

Heart failure with preserved ejection fraction is a common problem and its treatment is difficult. Disease modifying drugs for heart failure with reduced ejection fraction have not been effective in subjects with preserved ejection fraction. Treatment of ischaemic heart disease, arterial hypertension and rhythm and rate control in atrial fibrillation are the recommended therapeutic principles in this patient population. The research of pharmacotherapy focuses on new pathophysiologic pathways.

Keywords:
heart failure – preserved ejection fraction – pharmacotherapy

Sources

1. Yancy CW, Lopatin M, Stevenson LW et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (AD-HERE) Database. J Am Coll Cardiol 2006; 47(1): 76– 84.

2. Lam CS, Donal E, Kraigher-Krainer E et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13(1): 18– 28. doi: 10.1093/ eurjhf/ hfq121.

3. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355(3): 260– 269.

4. Steinberg BA, Zhao X, Heidenreich PA et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126(1): 65– 75. doi: 10.1161/ CIRCULATIONAHA.111.080770.

5. Solomon SD, Dobson J, Pocock S et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116(13): 1482– 1487.

6. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth! J Am Coll Cardiol 2010; 55(6): 526– 537. doi: 10.1016/ j.jacc.2009.06.067.

7. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359(23): 2456– 2467. doi: 10.1056/ NEJMoa0805450.

8. Cleland JG, Tendera M, Adamus J et al. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 2006; 27(19): 2338– 2345.

9. Campbell RT, Jhund PS, Castagno D et al. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-Preserved, and I-PRESERVE? J Am Coll Cardiol 2012; 60(23): 2349– 2356. doi: 10.1016/ j.jacc.2012.04.064.

10. Pitt B, Pffefer MA, Assman SF et al. The TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370(15): 1383– 1392. doi: 10.1056/ NEJMoa1313731.

11. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Europ Heart J 2016; 37(27): 2129– 2200. doi: 10.1093/ eurheartj/ ehw128.

12. Špinar J, Hradec J, Špinarová L et al. Souhrn doporučených postupů ESC pro diagnostiku a léčbu akutního a chronického srdečního selhání z roku 2016. Cor Vasa 2016; 58(5): e530– e568.

13. McKelvie RS, Komajda M, McMurray J et al. I-Preserve Investigators. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail 2010; 16(2): 128– 134. doi: 10.1016/ j.cardfail.2009.09.007.

14. van Veldhuisen DJ, Linssen GC, Jaarsma T et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013; 61(14): 1498– 1506. doi: 10.1016/ j.jacc.2012.12.044.

15. Yusuf S, Pfeffer MA, Swedberg K et al. The CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386): 777– 781.

16. Flather MD, Shibata MC, Coats AJ et al. The SENIORS Investigators. Randomised trial to determine the effect of nebivolol on mortality and hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3): 215– 225.

17. Ahmed A, Rich MW, Fleg JL et al. Effect of digoxin on morbidity and mortality in diastolic heart failure trial: the ancillary digitalis investigation group. Circulation 2006; 114(5): 397– 403.

18. van Veldhuisen DJ, Cohen-Solal A, Bohm M et al. The SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction. J Am Coll Cardiol 2009; 53(23): 2150– 2158. doi: 10.1016/ j.jacc.2009.02.046.

19. Zamani P, Rawat D, Shiva-Kumar P et al. Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 2015; 131(4): 371– 380. doi: 10.1161/ CIRCULATIONAHA.114.012957.

20. Bonderman D, Pretsch I, Steringer-Mascherbauer R et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest 2014; 146(5): 1274– 1285. doi: 10.1378/ chest.14-0106.

21. Pieske B, Butler J, Filippatos G et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 2014; 16(9): 1026– 1038. doi: 10.1002/ ejhf.135.

22. Redfield MM, Chen HH, Borlaug BA et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309(2): 1268– 1277. doi: 10.1001/ jama.2013.2024.

23. Solomon SD, Ziele M, Pieske B et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380(9851): 1387– 1395. doi: 10.1016/ S0140-6736(12)61227-6.